Erythropoietin Therapy for Hypoproliferative Bone‑Marrow Anemia

Initiation Criteria

Start EPO when hemoglobin falls to ≤10 g/dL in symptomatic patients with hypoproliferative marrow anemia. 1
Limit therapy to patients who require fewer than 2 red‑cell transfusions per month, as higher transfusion burden predicts poor response. 1
Measure baseline serum erythropoietin; values <500 IU/L (some guidelines <200 IU/L) are associated with better hematologic response. 1
Restrict use in myelodysplastic syndrome to low‑ or intermediate‑1 risk (IPSS) or very low‑ to intermediate‑risk (IPSS‑R). 1
Do not initiate EPO in patients whose baseline hemoglobin exceeds 12 g/dL, because higher baseline Hb is linked to increased mortality. 1

Fixed weekly dose: 30,000–80,000 IU recombinant human EPO administered subcutaneously once weekly.** 1
Darbepoetin alternative: up to 300 µg weekly subcutaneously.** 1
Three‑times‑weekly regimen: 150 U/kg subcutaneously three times per week; escalation to 300 U/kg after 4 weeks may be considered if response is inadequate.** 2

Assess hematologic response at 4–8 weeks after initiation. 1
Do not increase the EPO dose in non‑responders (except for epoetin theta), as studies have not shown benefit from dose escalation. 1
If no response after 8–12 weeks, add granulocyte‑colony stimulating factor (G‑CSF) 300 µg/week (divided doses) rather than increasing EPO dose. 1

Hemoglobin: check weekly after starting or after any dose change; aim to keep Hb between 10–12 g/dL and avoid rises >2 g/dL within 4 weeks.** 1
Iron status: obtain baseline ferritin, transferrin saturation, and total iron‑binding capacity; maintain ferritin >100 ng/mL and transferrin saturation >20 % to prevent functional iron deficiency.** 3

Thromboembolic risk: heightened in patients with high baseline thrombotic risk (e.g., multiple myeloma receiving immunomodulatory agents).** 2
Mortality: targeting Hb >12 g/dL is associated with increased mortality; maintaining Hb in the 10–12 g/dL range mitigates this risk.** 1

Stop EPO after 6–8 weeks if hemoglobin has risen <1–2 g/dL despite appropriate dosing and supportive care. 1
Consider alternative therapy (red‑cell transfusion or investigational agents) when treatment failure is confirmed. 1

Do not use EPO in patients who are heavily transfusion‑dependent (≥2 units/month) because response rates are low. 1
Avoid dose escalation in non‑responders; instead add G‑CSF or discontinue therapy. 1
Never target hemoglobin >12 g/dL, as this increases mortality and thrombotic complications. 1
Do not continue EPO beyond 8–12 weeks without a demonstrable response, to prevent unnecessary cost and delay alternative treatments. 1

The National Kidney Foundation recommends initial subcutaneous administration of 80-120 units/kg/week (typically 6,000 units/week) divided into 2-3 doses per week for patients with chronic kidney disease 4
The National Kidney Foundation suggests initial intravenous administration of 120-180 units/kg/week (typically 9,000 units/week) divided into 3 doses for patients with chronic kidney disease undergoing hemodialysis 4, 5
Pediatric patients ≤5 years with chronic kidney disease frequently require higher doses (300 units/kg/week) than older patients 4

The National Kidney Foundation recommends increasing the dose by 50% if hemoglobin increase is ≤2 percentage points over 2-4 weeks 5, 6
When switching from intravenous to subcutaneous administration, the subcutaneous dose should be 50% lower than the intravenous dose (or conversely, intravenous dose should be 50% higher than subcutaneous dose) 5, 6
If hemoglobin increases >3 g/dL (or hematocrit increases >8 percentage points) per month, reduce weekly dose by 25% 5, 6

The National Comprehensive Cancer Network recommends 40,000-60,000 subcutaneous units 1-2 times per week for patients with myelodysplastic syndromes and serum erythropoietin levels ≤500 mU/mL 7, 8
The FDA-approved starting dose for chemotherapy-induced anemia is 150 U/kg three times weekly or 40,000 U weekly subcutaneously 9, 10
The dose can be escalated up to 300 U/kg three times weekly for non-responders after 4 weeks 9, 10
For hepatitis C treatment-related anemia, 40,000 IU/week is the most frequently used dose 11

The National Kidney Foundation recommends checking hemoglobin weekly following initiation or dose adjustment to detect rapid responses or poor responses 5, 6
Less frequent monitoring (every 2 weeks or monthly) may miss critical changes and delay necessary dose adjustments 5, 6
Randomized trials demonstrate increased thromboembolism risk with ESAs, particularly in multiple myeloma patients receiving thalidomide/lenalidomide with doxorubicin or corticosteroids 9, 10
Discontinue treatment if no response (hemoglobin increase <1-2 g/dL) after 6-8 weeks with appropriate dose escalation 9, 10